Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 11 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
EXDENSUR — EXDENSUR
Application BLA761458 (BLA)
Wellbutrin — WELLBUTRIN XL
Application NDA021515
Wellbutrin — WELLBUTRIN SR
Application NDA020358
BLENREP — BLENREP
Application BLA761440 (BLA)
BLENREP — BLENREP
Application BLA761440 (BLA)
Lamictal — LAMICTAL ODT
Application NDA022251
Lamictal — LAMICTAL
Application NDA020241
Lamictal — LAMICTAL CD
Application NDA020764
Lamictal — LAMICTAL XR
Application NDA022115
Lamictal — LAMICTAL CD
Application NDA020764
Lamictal — LAMICTAL ODT
Application NDA022251
Lamictal — LAMICTAL
Application NDA020241
Lamictal — LAMICTAL XR
Application NDA022115
Lamictal — SUBVENITE
Application NDA218879 (NDA)
Zejula — ZEJULA
Application NDA214876
Benlysta — BENLYSTA
Application BLA761043
Benlysta — BENLYSTA
Application BLA125370
Utebzi — UTEBZI
Application NDA215960 (NDA)
Zejula — ZEJULA
Application NDA214876
Wellcovorin — VYKOURA
Application NDA220406 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)